http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017079120-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8c0982b0f02b1ed6d20a315370a3a3a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4406 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4409 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate | 2016-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2853fcd32a143a93b8cfd0c7f0c17ceb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f2431e9bab987b4145edd006c985337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24ed10ff46ffe31d405a5d7d0d6132a9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_049eff2948da94c02e223f51ff786937 |
| publicationDate | 2017-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2017079120-A1 |
| titleOfInvention | Ror gamma agonists as enhancers of protective immunity |
| abstract | The T cell specific RORgamma isoform RORgammat has been shown to be the key lineage-defining transcription factor to initiate the differentiation program of T H 17 and T C 17 cells, cells that have demonstrated anti-tumor efficacy, RORgammat controls gene networks that enhance immunity including increased IL17 production and decreased immune suppression. Agonists of RORgammat have been shown to increase the basal activity of RORgammat enhancing T H 17 cell proliferation. Here we show that activation of RORgammat using synthetic agonists drives proliferation of T H 17 cells while decreasing levels of the immune checkpoint protein PD-1, a mechanism that should enhance anti-tumor immunity while blunting tumor associated adaptive immune resistance. Interestingly, putative endogenous agonists drive proliferation of T H 17 cells but do not repress PD-1. These findings suggest that synthetic agonists of RORgammat should activate T c 17/T H 17 cells, decrease the population of Tregs, repress PD-1, and produce IL17 in situ , an immune factor associated with good prognosis in cancer. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020172467-A1 |
| priorityDate | 2015-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 423.